- Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) are chronic autoimmune disorders that significantly impact patient quality of life and increase the risk of severe organ damage, particularly affecting the kidneys in LN cases. The rising prevalence of autoimmune diseases, improvements in diagnostic capabilities, and advancements in targeted biologics are major factors driving market growth
- The increasing demand for advanced therapies is primarily fueled by a growing number of SLE and LN diagnoses, heightened awareness among patients and healthcare professionals, and the launch of novel biologic treatments such as belimumab and voclosporin
- North America dominated the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market with a revenue share of 37.6% in 2024, attributed to the region's advanced healthcare infrastructure, high disease awareness, strong reimbursement policies, and the presence of major pharmaceutical companies engaged in clinical trials and new product launches.
- Asia-Pacific is expected to be the fastest-growing region in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market during the forecast period, driven by increasing healthcare access, rising autoimmune disease prevalence, expanding clinical research efforts, and growing public and private investments in rare and chronic disease treatment
- The injection segment dominated the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market with a market share of 53.4% in 2024, owing to the high utilization of intravenous therapies for moderate to severe LN cases
